Molbio Diagnostics Targets ₹200 Crore from IPO Amid Global Expansion

Molbio Diagnostics is set to launch an initial public offering (IPO) aimed at raising ₹200 crore to enhance its capital expenditure. The company also plans to reduce its promoter group's stake by generating ₹740 crore through an offer for sale, which will lower the stake from 46.6% to 43%. The IPO is poised to attract investors with a high-risk appetite, promising potential long-term growth.

Strategic Expansion and Global Reach

Founded in 2000, Molbio Diagnostics has developed a robust presence in the molecular diagnostics sector, operating six manufacturing facilities across India. The company serves clients in over 90 countries, including government health programs, diagnostic labs, hospitals, and international healthcare organizations. A significant portion of its revenue, over 80%, comes from government and international aid agencies.

Molbio's flagship innovation, the 'Truenat' platform, is a portable diagnostic system designed for resource-limited settings. It provides accurate test results within an hour, catering to over 30 diseases through 43 diagnostic assays. Tuberculosis test kits are a major revenue driver, accounting for 70% of its diagnostic kit sales.

Financial Performance and Market Position

Molbio's financial performance between FY24 and FY26 has been strong, with revenue from operations rising 31.5% annually to ₹1,445.7 crore. The company's net profit surged by 40.2% to ₹164.1 crore in the same period. Additionally, the operating profit before interest, tax, depreciation, and amortization (EBITDA) increased by 33.2% to ₹328.2 crore, with an EBITDA margin improvement from 22% in FY24 to 22.6% in FY26.

In FY26, year-on-year growth was marked by a 41.7% revenue increase, a 27.9% rise in EBITDA, and an 18.4% increase in net profit. Molbio's valuation demands a price-earnings (P/E) multiple of up to 57, positioning it alongside other healthcare diagnostics and medical device firms like Poly Medicure and Dr. Lal PathLabs, which have P/E multiples ranging from 54 to 81.

Investment Considerations

The IPO aims to capitalize on Molbio's strategic expansions and the growing demand for its diagnostic solutions. While the company lacks directly comparable listed peers in India, its focus on innovative diagnostic technologies and significant revenue from international markets may attract investors seeking high-risk, high-reward opportunities. As Molbio continues to extend its global reach, the IPO could potentially deliver substantial long-term growth for investors willing to navigate the risks.